Soritene 0.1% cream is indicated for the topical treatment of patients with plaque psoriasis. It also works to treat acne.
Topical Tazarotene blocks ornithine decarboxylase (ODC) activity, which is associated with cell proliferation and hyperplasia. Tazarotene suppresses expression of MRP8, a marker of inflammation present in the epidermis of psoriasis patients at high levels. In human keratinocyte cultures, it inhibits cornified envelope formation, whose build-up is an element of the psoriatic scale. Tazarotene also induces the expression of a gene which may be a growth suppressor in human keratinocytes and which may inhibit epidermal hyperproliferation in treated plaques.
For psoriasis : Apply once daily in the evening usually for up to twelve weeks. Use and dose must be determined by the doctor of children upto 12 years of age. For acne : Cleanse the face gently. After the skin is dry, apply a thin layer of Tazarotene cream once per day, in the evening, to the skin areas where acne lesions appear. Use enough to cover the entire affeted area.
Generally Soritene cream is well-tolerated .The most frequent adverse events related to treatment with Soritene are skin-related as for example pruritus, erythema, burning, irritation, desquamation, stinging, contact dermatitis, dermatitis, eczema, worsening of psoriasis, skin pain, rash, hypertriglyceridemia, dry skin, skin inflammation, and peripheral edema.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Retinoids may cause fetal harm when administered to a pregnant woman. Tazarotene cream is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, treatment should be discontinued and the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be warned to the potential risk and use adequate birth-control measures when Tazarotene cream is used.
Concomitant dermatologic medications and cosmetics that have a strong drying effect should be avoided. It is also advisable to "rest" a patient’s skin until the effects of such preparations subside before use of Soritene cream is begun. Topical steroid may be hazardous in psoriasis; careful patient supervision is important. Consider if infection spreads. Do not use near a naked flame.
Soritene cream should be applied only to the affected areas. It is for external use only. Avoid contact with eyes, eyelids, and mouth. If contact with eyes occurs, rinse thoroughly with water. Retinoid should not be used on eczematous skin, as they may cause severe irritation. Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary and in such cases, exposure should be minimized during the use of Soritene cream. Soritene cream should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.